- Screening
- Preoperative indications
- Intraoperative indications
- Follow-up one week after aspiration
- Adverse events
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
- Design, Methods
|
Age ≥ 18 years old | Yes
|
|
Thyroid US indicates thyroid nodule. | Yes
|
|
US assessment accords with FNA criteria recommended by C-TIRADS | Yes
/No
|
|
nodule with high insufficient rate | nodule with macrocalcification
|
|
Informed consent | Yes
|
|
Allergic to lidocaine or SonoVue | No
|
|
Refuse to CEUS | No
|
|
Severe abnormality of heart function or lung function | No
|
|
Severe abnormality of coagulation function | No
|
|
Pregnancy | No
|
|
Active infectious focus on cervical skin | No
|
|
Patients unable to cooperate for FNA or CEUS | No
|
|
Registration number | 0001459760 |
|
Birthday | 1984-02-21 |
|
Sex | Female
|
|
Telephone | 13529839756 |
|
Date for signing informed consent | 2023-05-24 |
|
Location of target thyroid nodule | left lobe
|
|
transverse diameter | 12 mm |
|
Anteroposterior diameter | 9 mm |
|
Upper and lower diameter | 17 mm |
|
Solid component (%) | 100 |
|
echo | hypoecho
|
|
edge | unable to determine
|
|
border | unable to determine
|
|
acoustic halo | No
|
|
Strong echo within nodule | Sheet-like
|
|
Solid component of sheet-like strong echo (%) | 40 |
|
Score of ACR TI-RADS | 8 |
|
Rank of ACR TI-RADS | 5 |
|
Score of C-TIRADS | 2 |
|
Rank of C-TIRADS | 4b |
|
Ultrasonic diagnose | 甲状腺癌 |
|
VCs function evaluated by TLUSG | bilateral VCs moved symmetrically
|
|
Routine blood test | Yes
|
|
Coagulation function | Yes
|
- Time of aspiration
- Contrast-enhance indication (CEUS-FNA group)
- Progression of operation
- Intraoperative instant complication
|
Date of aspiration | 2023-05-24 |
|
Start time | 17：58 |
|
End time | 18：06 |
|
Dosage of SonoVue | - |
|
No enhancement | |
|
Ratio of enhancement | - |
|
Injection of SonoVue during FNA |
|
Machine | GE logiq E9
|
|
Local anesthesia | 2% lidocaine
|
|
other local anaesthesics | - |
|
Dosage of local anaesthesics | 4 ml |
|
Patient compliance | good
|
|
Aspiration needle | Italy 23G
|
|
FNA approach | isthmus approach
|
|
Aspiration times | 4 |
|
Use of negative pressure | No
|
|
Pressure | - ml |
|
Quality of nodule | solid
|
|
Grittiness | Yes
|
|
Sample capacity | a little
|
|
Allergic to contrast agent | No
|
|
Painful | No
|
|
VAS score | - |
|
Analgesic | No
|
|
Painful when leave interventional room | No
|
|
Haemorrhage | No
|
|
Voice change | No
|
|
Vagal nerve syndrome | No
|
|
Horner syndrome | No
|
|
Aspiration related acute hypersensitivity reaction | No
|
|
location | |
|
visible for bleeding by CDFI | |
|
extend of hematoma (once after FNA) |
|
|
methods | |
|
visible hemorrhage by CDFI 30 minutes after FNA | |
|
extend of hematoma (before patient departure) | |
|
appearance | |
|
vocal cord mobility assessment by ultrasound | |
|
methods | |
|
whether the voice recovers when the patient leaves |
|
Pathological number |
|
|
Whether sample capacity is enough | |
|
Number of observable follicular epithelial cell clusters in specimen | |
|
Cytopathology classification |